Tempest Therapeutics (NASDAQ:TPST) Trading Down 4.6% – What’s Next?

Shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) dropped 4.6% during mid-day trading on Thursday . The company traded as low as $2.28 and last traded at $2.29. Approximately 61,761 shares traded hands during trading, a decline of 23% from the average daily volume of 80,506 shares. The stock had previously closed at $2.40.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Tempest Therapeutics presently has a consensus rating of “Reduce” and an average target price of $12.50.

Tempest Therapeutics Stock Down 4.6%

The firm has a 50 day moving average price of $2.54 and a 200 day moving average price of $5.99. The stock has a market cap of $11.29 million, a PE ratio of -0.23 and a beta of -2.42.

Hedge Funds Weigh In On Tempest Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TPST. Sabby Management LLC purchased a new position in shares of Tempest Therapeutics in the 4th quarter worth approximately $513,000. Vanguard Group Inc. raised its stake in Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after acquiring an additional 27,952 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Tempest Therapeutics in the fourth quarter worth about $33,000. 22.52% of the stock is currently owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.